MicroRNAs and other non-coding RNAs as targets for anticancer drug development.
MicroRNAs and other non-coding RNAs as targets for anticancer drug development.
复制标题
DOI：
10.1038/nrd4140
复制
发表时间：
2013-11
期刊：
影响因子：
--
通讯作者：
Calin GA
中科院分区：
文献类型：
--
作者：
Ling H;Fabbri M;Calin GA
随着第一个癌症靶向microRNA药物MRX 34（一种基于脂质体的miR-34模拟物）于2013年4月进入晚期肝细胞癌患者的I期临床试验，miRNA治疗引起了学术界和生物技术公司的特别关注。尽管迄今为止研究最多的非编码RNA（ncRNA）是miRNA，但长链非编码RNA（lncRNA）的重要性正日益被认识到。在这里，我们总结了miRNA和lncRNA在癌症中的作用，重点是最近发现的新的作用机制，并讨论了当前设计ncRNA靶向治疗方法的策略，以及相关的挑战。
With the first cancer-targeted microRNA drug, MRX34, a liposome-based miR-34 mimic, entering phase I clinical trial in patients with advanced hepatocellular carcinoma in April 2013, miRNA therapeutics are attracting special attention from both academia and biotechnology companies. Although to date the most studied non-coding RNAs (ncRNAs) are miRNAs, the importance of long non-coding RNAs (lncRNAs) is increasingly being recognized. Here we summarize the roles of miRNAs and lncRNAs in cancer, with a focus on the recently identified novel mechanisms of action, and discuss the current strategies in designing ncRNA-targeting therapeutics, as well as the associated challenges.